Nautilus Biotechnolgy, Inc. NAUT 深 滬
等待開盤 03-26 09:30:00 美东时间
3.91
-0.040
-1.01%
華盛通- 最 高4.3101
- 今 開4.00
- 成交量 100.97万股
- 最 低 3.7621
- 昨 收 3.95
- 總市值 4.95亿
- 52周最高 4.3101
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 0.62
- 委 比 -36.64%
- 總股本 1.27亿
- 歷史最高 12.38
- 量 比 1.58
- 振 幅 13.87%
- 歷史最低 0.62
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Curanex Pharmaceuticals (NASDAQ:CURX) shares moved upwards by 57.7% to...
02-27 01:05
Nautilus Biotechnology Q4 EPS $(0.11) Beats $(0.14) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 21.43 percent increase over losses of $(0.14) per share
02-26 19:11
Nautilus Biotechnology Debuts Voyager Platform To Power Iterative Mapping Of Up To 10B Intact Proteins And Proteoforms Simultaneously In Single Run
Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today debuted the Voyager™ Platform, which is designed to power the Iterative Mapping of up to 10 billion intact
02-24 21:07
Nautilus Biotechnology, Weill Cornell Medicine-Qatar And Michael J. Fox Foundation Collaborate To Study Connection Between Alpha-Synuclein Protein And Parkinson's Disease
Support from The Michael J. Fox Foundation for Parkinson's Research to advance critical research into Parkinson's disease biology • Nautilus' development of a single-molecule assay for measuring alpha-synuclein
01-28 21:03
Nautilus Biotechnology Advances Toward 2026 Commercial Launch
Nautilus Biotechnolgy, Inc. ( ($NAUT) ) has released its Q3 earnings. Here is a...
2025-10-29 12:29
电话会总结 ｜ Nautilus(NAUT)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Nautilus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2025年第三季度核心财务数据：** - 总运营费用：1,550万美元 - 研发费用：960万美元 - 一般管理费用：590万美元 - 净亏损：1,360万美元 - 现金消耗：1,100万美元 - 期末现金、现金等价物及投资：16,850万美元 ## 2. 财务指标变化 **同比变化（2025年Q3 vs 2024年Q3）：** - 总运营费用：从1,910万美元降至1,550万美元，同比下降19% - 研发费用：从1,230万美元降至960万美元，同比大幅下降
2025-10-29 12:24
Nautilus Biotech Earnings Call Highlights Strategic Progress
Nautilus Biotechnolgy, Inc. (($NAUT)) has held its Q3 earnings call. Read on fo...
2025-10-29 08:23
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
